The term meconium was originally coined by Aristotle who used the Greek word meconium-arion 1 meaning "opium-like," because he believed meconium induced fetal sleep. It is probable that he recognized the association between the presence of meconium in the amniotic fluid and the occurrence of fetal deaths and neonatal depression.
observed a sevenfold increased risk of neonatal seizures and a fivefold increased likelihood of hypotonia in infants born through moderate to thick compared with thin meconium-stained or clear amniotic fluid. Some investigators have noted an increased likelihood of cerebral palsy in surviving infants with a low Apgar score who were born through MSAF. 17 In addition, there may be long-term pulmonary sequelae associated with MAS. Yuksel et al. 18 have shown increased functional residual capacity and airway reactivity at 6 months of age in infants with MAS; infants who required more respiratory support in the neonatal period had significantly more symptoms and required bronchodilator therapy more often. MAS has also been implicated in increased airway reactivity and abnormal pulmonary function tests in later childhood. 19, 20 
PATHOPHYSIOLOGY OF MECONIUM PASSAGE
Meconium is a viscous green substance composed primarily of water (72% to 80%). Other components of meconium include gastrointestinal secretions, bile, bile acids, mucus, pancreatic juice, cellular debris, and swallowed amniotic fluid, lanugo, vernix caseosa, and blood. 1, 21 The substance may first be noted in the fetal gastrointestinal tract as early as 10 to 16 weeks' gestation. At birth, 60 to 200 gm of meconium may be present in the intestinal tract of a term infant.
In utero passage of meconium is uncommon because of a lack of strong peristalsis, the presence of a tonically contracted anal sphincter, and the presence of a terminal cap of viscous meconium. For many term and post-term infants, passage of meconium is probably a physiologic maturational event. Meconium passage is rare before 37 weeks' gestation 22 but may occur in more than one-third of pregnancies lasting longer than 42 weeks. 23, 24 The levels of motilin, a hormone known to be responsible for gastrointestinal motility in adults, have been shown to be higher in term and post-term than in preterm infants, 25 supporting the hypothesis that maturation of the gastrointestinal tract has a large role to play in the passage of meconium.
Passage of meconium, in utero, has also been associated with anteor intrapartum fetal acidemia. 6, 24 Alexander et al. 9 observed a twofold increase in the odds of MSAF if fetal stress was present. It has been postulated that fetal hypoxia will result in increased intestinal peristalsis with relaxation of the anal sphincter, resulting in passage of meconium. A distressed, gasping fetus might be prone to aspirating meconium, a phenomenon more likely to occur in term and post-term than in preterm neonates. In addition, it has been speculated that oligohydramnios may result in compression of the fetal head or the umbilical cord, resulting in a vagal response and meconium passage.
asphyxia or the meconium itself ( Figure 1 ). Some investigators 4, 14, 26 have shown an increased likelihood of MAS with thick compared with moderate or thin meconium. Although Bhutta and colleagues 11 did not observe an association, Wiswell et al., 27 in a large multicenter trial, demonstrated a direct relationship between meconium thickness and severity of respiratory disease.
It has been reported that an ominous fetal heart rate tracing and evidence of more severe fetal asphyxia, including lower umbilical artery pH and Apgar scores, were predictive of a prolonged need for mechanical ventilation in infants with MAS. 28 Yeh et al. 29 noted that consolidation or atelectasis on chest radiography appeared to be most predictive of poor outcome. On the other hand, Valencia and colleagues 30 were unable to accurately predict illness severity in infants with MAS using the admission chest radiograph.
Aspiration of meconium can cause either partial or complete obstruction of the airways. Partial obstruction of the airways results in a "ball-valve effect," with areas of atelectasis and air trapping, and subsequent development of air leaks. Complete airway obstruction leads to alveolar collapse and ventilation-perfusion mismatch. In an adult rabbit model of MAS, Tyler et al. 31 demonstrated early onset of airway obstruction as evidenced by alveolar collapse, ventilationperfusion mismatch, and increased functional residual capacity. In a similar model, it has been shown that mechanical dysfunction in lungs is most severe during the early phase of MAS, with diminished dynamic and specific lung compliance, but unchanged static lung compliance, suggestive of partial random obstruction of large airways. 32 This study, however, is limited in its duration, and effects occurring more than 2 hours following meconium aspiration were not evaluated. Similar findings were observed by Yeh and colleagues 33 who evaluated pulmonary function tests in the first 3 days of life in neonates with mild MAS not requiring mechanical ventilation. They demonstrated lower dynamic and specific lung compliance and increased airway resistance in these infants compared with control infants.
The presence of meconium in the airways can also induce an inflammatory response. In a retrospective review of autopsied cases with histologic evidence of meconium exposure, 34 67% of all cases with pulmonary inflammation were noted to be secondary to meconium aspiration. In a rabbit model, the later stages of MAS are characterized by microvascular endothelial damage with development of an intrapulmonary shunt, alveolar collapse, and cellular necrosis, consistent with chemical pneumonitis. 31 In addition, in vitro studies on alveolar macrophages have demonstrated both increased superoxide anion 35 and thromboxane 36 production. Cord blood neutrophils have been shown to have increased chemotaxis in response to meconium, possibly secondary to the presence of interleukin-8 in meconium. 37 Meconium has also been shown to inhibit neutrophil oxidative burst and phagocytosis. 38 With a pulsating bubble surfactometer or a Wilhelmy balance, meconium has been shown to inhibit pulmonary surfactant function. 39 -41 In isolated rat alveolar cells, at low concentrations of meconium, Higgins et al. 42 demonstrated absence of toxicity to type II pneumocytes. However, at higher concentrations of meconium (Ͼ1%), they demonstrated dose-dependent cytotoxicity that was inhibited in the presence of heat-treated meconium, suggesting that a protein moiety may be partly responsible for this action. 42 A cytotoxic effect of meconium has also been inferred by other investigators who have demonstrated decreased production of surfactant protein-B (SP-B) in the presence of high concentrations of meconium. 43 As many as one-third of infants with MAS develop PPHN, 13 and approximately two-thirds of infants with PPHN have associated meconium aspiration. 13, 44 The development of PPHN may be a result of acidosis, hypoxia, or hypercapnea associated with aspiration of meconium, or to acute or chronic hypoxia in utero. Cornish et al. 45 failed to produce clinical or histologic evidence of PPHN in a neonatal baboon model of acute perinatal asphyxia and/or meconium aspiration. Neonatal pulmonary vessels are known to exhibit greater vasoconstrictive responses than adult pulmonary arteries. 46 In addition, these vessels possess a unique ability to undergo rapid changes in architecture, particularly thickening of the media and the adventitia, distal extension of smooth muscle, 47 and increased tortuosity and muscularization of the alveolar septal arterioles. 48 The importance of this abnormal proliferation and excessive collagen synthesis by pulmonary vascular wall cells has been demonstrated by attenuation of the pulmonary hypertensive process by inhibitors of collagen synthesis in a rat model. 49 Similar findings of excessive muscularization of distal pulmonary arterioles in infants with fatal MAS 50 were discounted by Perlman and colleagues 51 who suggested that these findings could be an artifact caused by distortion of the pulmonary vessels during fixation.
PREVENTION OF MAS
The objective of this review was to report the status of resuscitation of meconium-stained infants and the current management for prevention of MAS and to examine the controversies therein. The complex issues regarding management of PPHN have been dealt with in another review.
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PRENATAL MANAGEMENT Amnioinfusion
Since the initial description of amnioinfusion for the relief of repetitive intrapartum variable decelerations in the 1980s, substantial interest has been generated in the use of amnioinfusion for prevention of neonatal morbidity associated with MSAF. It is theorized that increasing the amniotic fluid volume will result in dilution of meconium, with possible decrease in toxicity of the components of meconium. It has been shown that aspiration of thin meconium may result in fewer and less severe respiratory complications compared with aspiration of moderate to thick meconium. 4, 26, 27 Furthermore, in the presence of oligohydramnios, which like MSAF is more often found in post-term pregancies, cord compression may be relieved by increasing amniotic fluid volume, which potentially prevents fetal hypoxia and acidosis, further meconium passage, fetal gasping, and in utero aspiration of meconium. Several retrospective analyses 53, 54 and randomized clinical trials [55] [56] [57] [58] [59] [60] [61] have assessed the effectiveness of amnioinfusion for improving neonatal outcomes. Some have shown improved acid-base balance in the fetus 55, 61 and decreased likelihood of meconium below the cords 60, 62 and MAS, 55, 56, 60 whereas others have not. 53, 58 These differing results may, in part, be explained by the relatively small sample sizes of these studies and their differing study designs. In a retrospective study involving the largest sample studied to date, Usta et al. 53 were unable to demonstrate any difference in neonatal outcomes in infants born to women who had received amnioinfusion for MSAF compared with women who had not received amnioinfusion. Moreover, they noted a higher incidence of fetal heart rate abnormalities and an increased likelihood of instrumental delivery and endometritis in women who received amnioinfusion. Thus, amnioinfusion for the prevention of MAS should be considered an experimental therapy until its efficacy is confirmed by a large randomized clinical trial.
POSTNATAL MANAGEMENT Delivery Room Management
Oropharyngeal suctioning. After demonstrating a decrease in the incidence of MAS following institution of oropharyngeal suctioning at the perineum, Carson and colleagues 10 advocated this therapy in all infants born through MSAF. They concluded that, with effective oropharyngeal suctioning at the perineum, the risks of endotracheal suctioning were not warranted if meconium was not visualized below the vocal cords. In contrast, in a prospective observational study in the early 1990s, Falciglia et al. 5 failed to demonstrate a decrease in the incidence of meconium below the vocal cords or MAS in infants who had received early oropharyngeal suctioning (after delivery of the head) compared with late suctioning (after delivery of the chest). A more recent study, 63 has demonstrated better 1-and 5-minute Apgar scores, fewer abnormalities on chest radiography, and less need for mechanical ventilation in infants born through MSAF who were suctioned at the perineum. Based on these findings and the 1992 American Academy of Pediatrics/American Heart Association (AAP/AHA) 64 recommendations, suctioning of the oropharynx at the perineum remains an important aspect of management of infants born through MSAF.
Cricoid pressure, epiglottal blockage, and thorax compression. Cricoid pressure involves applying pressure to the airway to prevent meconium from descending into the lungs. With epiglottal blockage, one or more fingers are placed down an infant's airway to apply pressure on the epiglottis and block the airway. Both these maneuvers have the potential for traumatizing a neonate's airway and can induce a vagal response. Compression of the thorax involves encircling a neonate's chest with one's hands and applying pressure to prevent the newborn from inhaling deeply and aspirating more meconium. This too is a potentially dangerous practice with the possibility of trauma and aspiration secondary to chest recoil when the encircling hands are removed. 65 Although they are in use, these maneuvers have not been adequately investigated. 66 or even an increased risk. 7, 67 These varying results are probably secondary to the small sample sizes and differing study designs. A selective intubation approach was suggested by Cunningham and colleagues 68 ; they recommended intubation only of depressed infants born through MSAF. Based on available data, in 1992, the AAP and AHA 64 recommended intrapartum suctioning of the airway at the perineum after delivery of the head and tracheal suctioning of depressed infants and those born through thick, particulate meconium. The members of the committee felt that if the infant was active and the meconium was thin and watery, thorough suctioning of the oropharynx at the time of delivery of the head may be adequate.
In a recent, prospective, multicenter, randomized, clinical trial, Wiswell et al. 27 have observed an increased likelihood of respiratory complications in infants born through moderate (6.3%) and thick (15.4%) meconium compared with those born through thin meconium (2.3%). They were, however, unable to demonstrate any difference in the incidence of MAS or other respiratory complications in apparently vigorous infants who were randomized to intubation and tracheal suctioning compared with expectant management. 27 The incidence of complications secondary to intubation was low (3.8%), with all complications being transient. Based on the findings of this clinical trial, the largest to date, the authors recommend routine tracheal suctioning only for depressed infants and those with respiratory symptoms.
Chest physiotherapy. In any infant, the objectives of chest physiotherapy are to prevent accumulation of debris and to improve mobilization of airway secretions, with consequent improvement in gas exchange. Therefore, chest physiotherapy should perform a similar function in neonates who have aspirated meconium. However, data to support this practice are lacking. Numerous complications, including pneumothoraces, hypoxemia, arrythmias, and tissue damage, have been reported with this procedure; hence, its routine use in infants who have aspirated meconium is not yet justified.
MAS and Surfactant
In several in vivo 40, 41, 69 and in vitro 39 -41 studies, meconium has been shown to inhibit surfactant function in a dose-dependent manner. 41 This inhibition of surfactant function can be overcome with sufficiently high concentrations of surfactant, 39 suggesting that meconium may inhibit surfactant function by competing with surfactant molecules for space at the air-liquid interface. Bae and colleagues 70 have recently reported the in vitro effects of meconium on the surface tension-lowering properties and the ultrastructural morphology of pulmonary surfactant. Meconium/surfactant ratios exceeding 2.0 were found to be associated with marked increases in the minimum surface tension of Surfacten (the Japanese equivalent of beractant [Survanta; Ross Pharmaceuticals, Columbus, OH]). This increase in surface tension corresponded to ultrastructural changes in the surfactant, with the normal loosely stacked layers being replaced by spherical lamellar and folded linear structures. Higgins et al. 42 have demonstrated toxicity to cultured rat alveolar type II cells with high concentrations of meconium. In a rat model of MAS, decreased levels of SP-A and SP-B were observed in the bronchoalveolar lavage fluid. 71 Considering these data, it seems logical to suppose that surfactant replacement therapy in infants with MAS will improve pulmonary outcome.
In a newborn piglet model of MAS, 72 69, 73 In a prospective, uncontrolled study, Auten et al. 74 showed improved oxygenation in infants with MAS treated with calf lung surfactant extract. Small retrospective studies have shown variable results with one 75 showing improved oxygenation and a decreased oxygenation index and the other 76 showing inconsistent results in infants with MAS treated with surfactant. This variability in response to exogenous surfactant could be secondary to the timing of surfactant administration or to the preparation of surfactant used. Davis and colleagues 77 have observed improved oxygenation and ventilation in a small group of infants with MAS who were treated with a combination of high-frequency jet ventilation and calf lung surfactant extract replacement after deterioration in respiratory status while receiving conventional mechanical ventilation and exogenous surfactant therapy. The importance of surfactant function in infants with MAS has been partly elucidated by Bui et al. 78 who demonstrated a dramatic increase in phospholipid, disaturated phosphatidylcholine, and SP-A levels in the tracheal aspirate of infants on extracorporeal membrane oxygenation for respiratory failure just before the cessation of oxygenation. Using beractant at a dose of 6 ml/kg (one and a half times the standard dose used for respiratory distress syndrome) infused over 20 minutes, Findlay and colleagues 79 demonstrated improved oxygenation, decreased incidence of air leaks and a reduced likelihood of requiring extracorporeal membrane oxygenation in infants treated with surfactant within 6 hours of birth compared with control patients. Importantly, the investigators did not observe any improvement in the respiratory status of their study infants until the second dose of surfactant, a finding suggestive of inadequate dosing with surfactant in these infants. More research, however, is needed to establish the exact role of surfactant in management of these infants, including the optimal dose(s), timing of administration, type of surfactant, and the mode of delivery (bolus, continuous infusion, or lavage). A newer synthetic surfactant (Surfaxin; Discovery Laboratories, Inc., Doylestown, PA) contains a mixture of phospholipids and the KL 4 peptide (a synthetic peptide with physicochemical properties of SP-B). Because increasing concentrations of SP-B in surfactant preparations have been shown to confer enhanced resistance to inactivation by protein, 80 Surfaxin may prove to be a useful therapy in neonates with MAS.
MAS and Lung Lavage
Because it is impossible to estimate the amount of meconium aspirated by an infant and its effect on surfactant function, it is not feasible to estimate a correct dose of surfactant for each affected infant without performing bronchoalveolar lavage and estimating surfactant function in the lavage fluid. Furthermore, surfactant boluses are more likely to reach areas with better aeration than those that are collapsed or contain debris, resulting in ventilation-perfusion mismatch. Hence, lavage of the airways may be a reasonable alternative to administration of bolus exogenous surfactant to these infants. Lavage of airways with either saline or surfactant might also remove residual meconium and inflammatory mediators, with subsequent decrease in pulmonary symptoms secondary to airway obstruction and inflammation. The following two methods have been suggested for lung lavage: saline lavage followed by exogenous surfactant administration, or surfactant lavage with or without subsequent surfactant bolus(es).
In a newborn piglet model of MAS, 81 saline lavage, either alone or in combination with exogenous beractant replacement, failed to result in improvement in oxygenation and ventilation. In animal models with MAS, surfactant lavage (as compared with no lavage or saline lavage) has been shown to result in improved gas exchange [82] [83] [84] and increased meconium recovery. 83 Improved dynamic compliance 85 has been observed in a rat model with meconium aspiration following Surfaxin lavage compared with saline lavage. Investigators have shown a beneficial effect of higher positive end expiratory pressure with Surfaxin lavage in animals with meconium aspiration. 86 Following Surfaxin lavage, compared with saline or perfluorocarbon lavage, Antunes and colleagues 87 have observed elevated disaturated phosphatidylcholine, SP-A, and SP-B levels in a rat model of MAS. In a small group of four patients with severe respiratory failure secondary to MAS, Ogawa and colleagues 88 demonstrated marked improvement in oxygenation and ventilation after surfactant (Surfacten) lavage. These infants tolerated the procedure without any detectable ill effects. Currently, Wiswell and colleagues are evaluating the safety and efficacy of surfactant lavage (using Surfaxin) compared with routine management in infants with moderate-to-severe MAS; until completion of that trial, surfactant lavage for treatment of MAS should be considered an experimental therapy.
MAS and Early Steroids
Aspiration of meconium has been shown to be associated with inflammatory changes in the lungs, including increased absolute neutrophil count and chemotactic activity, 89 increased production of superoxide anions 35 and cytokines, such as thromboxane, 36 by alveolar macrophages, and decreased neutrophil oxidative burst and phagocytosis. 38 Because glucocorticoids have potent anti-inflammatory properties, it is conceivable that they may be able to ameliorate, in part, the inflammation associated with aspiration of meconium. In a rabbit pup model of MAS, Frantz and colleagues 90 showed decreased survival in animals who received cortisol following meconium aspiration; however, the steroid treated animals that survived had lower respiratory rates and better lung histopathology scores than did control animals. In contrast to these findings, in pretreated adult pigs, 91 methylprednisone was shown to decrease pulmonary vascular resistance and improve oxygenation in animals that had aspirated meconium. These differing results could stem from differences in the timing of the meconium aspiration (newborn versus older animals) and steroid therapy (treatment before versus following meconium aspiration).
Davey and colleagues 92 have shown decreased alveolar white cells in tracheal aspirate from infants with MAS who were treated early with dexamethasone. In a randomized, clinical trial, Yeh et al. 93 showed an increased duration of mechanical ventilation and supplemental oxygen requirement in infants with MAS who were treated with steroids. It is to be noted, however, that very few infants in either group required mechanical ventilation. More recently, in a randomized clinical trial, Yeh and colleagues 94 have shown improved oxygenation and ventilation indices and decreased duration of mechanical ventilation in infants with MAS who were treated early with dexamethasone. However, in both the treatment and control groups, less than 50% of the infants required mechanical ventilation. The results of this early trial are promising; however, a large clinical trial involving infants with significant MAS requiring mechanical ventilation is needed to confirm these findings.
CONCLUSIONS
The occurrence of MSAF and MAS is a relatively common problem faced by pediatricians and neonatologists. MAS is a complex disorder, with symptoms ranging from mild respiratory distress to PPHN, with death resulting in some infants. The importance of this clinical syndrome lies in the significant morbidity and mortality attributable to it. Our understanding of the pathophysiology of MAS remains limited, which hampers the development of newer and better treatment options.
Although both prenatal and postnatal interventions are used widely in an effort to prevent MAS, most have not yet been adequately investigated. Oropharyngeal suctioning at the perineum by obstetricians continues to be an important aspect of management in these infants. The controversial issue of tracheal suctioning has been recently clarified in a large, randomized clinical trial-tracheal suctioning should be reserved for infants who are depressed at birth or are manifesting signs of respiratory distress; intubation and suctioning of vigorous meconium-stained infants does not result in a decreased incidence of respiratory complications. Although widely used, the role of amnioinfusion in the prevention of MAS remains controversial; a large randomized clinical trial is needed to elucidate its role, if any. The roles of postnatal steroids, exogenous surfactant administration, and surfactant lavage in the management of infants with MAS need to be further investigated, especially as regards their efficacy and safety.
